Successful Medical Management of Life-threatening Hepatic Hemangioma in Neonates

Complicated HHs carry a high risk of morbidity; we report 2 cases of life-threatening HH that were managed successfully with medical therapies. Hepatic hemangioma (HH) is a common asymptomatic, self-limiting benign vascular tumor of the liver in neonates. Although complicated HHs are rare, they have significant risks of morbidity and mortality, especially during the perinatal period. Because of the high risks of complications from surgical interventions, there is an unmet need for effective medical therapy. We report 2 neonates with life-threatening HH who were evaluated for a liver transplant before being treated successfully with combined medical therapy, which included sirolimus, corticosteroids, and propranolol.

[1]  Yi Ji,et al.  Efficacy of propranolol treatment in infantile hepatic haemangioma , 2019, Journal of paediatrics and child health.

[2]  D. Adams,et al.  Guidance Document for Hepatic Hemangioma (Infantile and Congenital) Evaluation and Monitoring , 2018, The Journal of pediatrics.

[3]  J. López-Gutiérrez.  Clinical and economic impact of surgery for treating infantile hemangiomas in the era of propranolol: overview of single-center experience from La Paz Hospital, Madrid , 2018, European Journal of Pediatrics.

[4]  A. Morimoto,et al.  Successful use of propranolol for congenital hepatic hemangioma with Kasabach–Merritt phenomenon , 2017, Pediatrics international : official journal of the Japan Pediatric Society.

[5]  J. Mulliken,et al.  Somatic Activating Mutations in GNAQ and GNA11 Are Associated with Congenital Hemangioma. , 2016, American journal of human genetics.

[6]  R. Azizkhan,et al.  Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies , 2016, Pediatrics.

[7]  D. Zurakowski,et al.  Risk factors for mortality in patients with multifocal and diffuse hepatic hemangiomas. , 2015, Journal of pediatric surgery.

[8]  A. Fogel,et al.  Advances in the therapeutic use of mammalian target of rapamycin (mTOR) inhibitors in dermatology. , 2015, Journal of the American Academy of Dermatology.

[9]  T. Kuroda,et al.  Critical hepatic hemangioma in infants: Recent nationwide survey in Japan , 2014, Pediatrics international : official journal of the Japan Pediatric Society.

[10]  E. Lehmann,et al.  Rapidly involuting congenital haemangioma (RICH) of the liver , 2012, Pediatric Radiology.

[11]  E. Boscolo,et al.  Rapamycin Suppresses Self-Renewal and Vasculogenic Potential of Stem Cells Isolated from Infantile Hemangioma , 2011, The Journal of investigative dermatology.

[12]  J. Mulliken,et al.  Hepatic hemangiomas: subtype classification and development of a clinical practice algorithm and registry. , 2007, Journal of pediatric surgery.